Capricor Therapeutics reported a net loss of $33.9 million for Q1 2026 as it advances its Duchenne muscular dystrophy treatment, Deramiocel, which is under active FDA review with a PDUFA date set for August 22, 2026. The company is preparing for commercial launch with an operational GMP manufacturing facility and plans to expand capacity by 2027. Legal action was taken against its distributor NS Pharma to resolve pricing and access issues, but this does not affect the FDA review timeline. Capricor holds about $279 million in cash, expected to fund operations through late 2027, and may receive a Priority Review Voucher upon approval, providing potential additional capital.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
